Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
covid save search
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 4.21%
H: 1.01%
C: 1.01%
cm04 covid-19 vaccine congress world
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 3.71%
H: 3.45%
C: 2.3%
covid-19 bemnifosbuvir antiviral pharmaceuticals global trial
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Published: 2024-03-26 (Crawled : 13:00) - globenewswire.com
VIRI | $0.4393 -2.36% -2.41% 59K
|
Health Technology
|
| O: 4.41%
H: 8.05%
C: -12.31%
patent antiviral international publication treatment therapeutics
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
Published: 2024-03-22 (Crawled : 19:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
| Email alert
Add to watchlist
vyd222 covid-19 fda authorization
Global Medical Device Connectivity Market Poised for Substantial Growth: In-Depth Analysis Reflects Impacts of COVID-19 and Predicts Surge through 2029
Published: 2024-03-21 (Crawled : 15:30) - prnewswire.com
ORCL | $114.88 -0.97% 0.01% 8.2M
|
Technology Services
|
| O: 0.99%
H: 1.73%
C: -1.16%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.56%
H: 0.5%
C: -0.19%
INFY | $16.81 1.82% -1.31% 15M
|
Technology Services
|
| O: -3.06%
H: 0.76%
C: -0.76%
LTRX | $3.105 -1.43% -1.45% 150K
|
Distribution Services
|
| O: 1.12%
H: 1.67%
C: 0.28%
DGII | $29.32 -0.95% -0.95% 170K
|
Electronic Technology
|
| O: 0.98%
H: 0.77%
C: 0.37%
CSCO | $48.33 0.46% 0.46% 20M
|
Technology Services
|
| O: 0.32%
H: 0.97%
C: 0.34%
covid-19 device global medical market
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
TSOI | $0.0007 0.0% 33M
|
Manufacturing
|
| O: 10.0%
H: 18.18%
C: 9.09%
covid-19 quadramune patent natural granted international cell solutions
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
Published: 2024-02-21 (Crawled : 19:00) - biospace.com/
LGST | $4.51 -11.31% 13K
|
n/a
| Email alert
Add to watchlist
covid company genetic cell treatment potential therapy study
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.1285 490.75% 32K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.09%
C: -5.9%
covid-19 drug antiviral trial
Global Cruise Industry Trends Report 2024: COVID-19 Impacts, Company Case Studies, Sector Deals, Advertisement Activity, Challenges and Opportunities
Published: 2024-02-19 (Crawled : 23:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
covid-19 company report global trends
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
NNVC | $1.1 -6.38% 0.0% 22K
|
Health Technology
|
| O: 2.56%
H: 0.83%
C: -0.83%
nv-387 covid report treatment trial
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: 0.89%
H: 3.42%
C: -0.88%
covid-19 update trial
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
Published: 2024-02-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
covid-19 sales drug
QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: -1.25%
H: 0.07%
C: -1.63%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: -1.25%
H: 0.07%
C: -1.63%
sales growth
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 2.77%
H: 2.69%
C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
AIMD | $1.03 1.92% 21K
|
Manufacturing
|
| O: 11.65%
H: 0.0%
C: -6.09%
covid-19 fda drug resolve trial response
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Published: 2024-02-05 (Crawled : 13:30) - prnewswire.com
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.